Código QR

Eligibility for vericiguat in a real‐world, contemporary heart failure population

Abstract Aims Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real‐world data on how many patients could be eligible for vericiguat therapy derive from ou...

Descripción completa

Guardado en:
Autores principales: Giuseppe Vergaro, Alberto Aimo, Francesco Gentile, Giulia Elena Mandoli, Marta Focardi, Vincenzo Castiglione, Alberto Giannoni, Giorgia Panichella, Alessandra Fornaro, Erberto Carluccio, Riccardo Liga, Mattia Salatin, Claudio Passino, Massimo F. Piepoli, Matteo Cameli, Francesco Cappelli, Carlo Di Mario, Michele Emdin
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2024-12-01
Colección:ESC Heart Failure
Materias:
Vericiguat
Heart failure
Therapy
Guidelines
Population
Acceso en línea:https://doi.org/10.1002/ehf2.14767
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares